Thumbnail Image
Publication

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Cuzick, J
; 
Sestak, I
; 
Baum, M
; 
Buzdar, A
; 
Howell, Anthony
; 
Dowsett, M
; 
Forbes, J
Citations
Altmetric:
Abstract
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months.
Authors
Cuzick, J
Sestak, I
Baum, M
Buzdar, A
Howell, Anthony
Dowsett, M
Forbes, J
Affiliation
Cancer Research UK, Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary School of Medicine and Dentistry, University of London, London, UK. j.cuzick@qmul.ac.uk
Description
Date
2010-12
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Breast Cancer
Cancer Staging
Type
Article
Citation
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. 2010, 11 (12):1135-41 Lancet Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/121326
Embedded videos